Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769161 | 1.00 | TSHR (0.58) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL137704 | 0.86 | TSHR (0.58) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL15703077 | 0.84 | TSHR (0.60) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL30908542 | 0.84 | TSHR (0.60) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL28778586 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL7592333 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL27794455 | 0.81 | TSHR (0.56) | TSHRCYP3A4MCOLN3KAT2BMEN1 | |
| SCHEMBL23668294 | 0.80 | ALDH1A1 (0.52) | TSHRCYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2062571 | 0.80 | MAPK1 (0.58) | TSHRMEN1KMT2ASMN1; SMN2VCAM1 | |
| SCHEMBL20651236 | 0.80 | TSHR (0.60) | TSHRCYP3A4MCOLN3KAT2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20180030503-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
| US-20180030503-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
| US-9816127-B2 | Oxidized glutathione assay | PROMEGA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-9816127-B2 | Oxidized glutathione assay | PROMEGA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-9816127-B2 | Oxidized glutathione assay | PROMEGA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2611929-B1 | OXIDIZED GLUTATHIONE ASSAY | PROMEGA CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
| EP-2675526-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | Vifor (International) AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| EP-2611929-A1 | OXIDIZED GLUTATHIONE ASSAY | Promega Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| WO-2012030960-A1 | OXIDIZED GLUTATHIONE ASSAY | PROMEGA CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030960-A1 | OXIDIZED GLUTATHIONE ASSAY | PROMEGA CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120058501-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-03-08 | — | — | US | disclosed |
| US-20120058501-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-03-08 | — | — | US | disclosed |
| US-20120058501-A1 | OXIDIZED GLUTATHIONE ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | TSHR 2338/4885CYP3A4 2645/4885MCOLN3 2593/4885 |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | TSHR 1004/4885CYP3A4 2693/4885MCOLN3 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.